KRAS mutations are among the most prevalent oncogenic drivers implicated across a broad spectrum of human cancers. The protein regulates critical cellular processes by orchestrating proliferation and survival pathways, making it a prime therapeutic target. However, the development of inhibitors capable of robustly modulating pan-KRAS activity has been hindered for decades by the exceptionally high affinity of KRAS for guanine nucleotides (GDP/GTP) and the scarcity of well-defined, druggable pockets on its surface. These properties have rendered conventional small-molecule approaches largely ineffective, spurring demand for novel strategies that can circumvent these biological constraints.

Recognizing this challenge, the team at Insilico Medicine applied their AI-driven platform, Chemistry42, to design a diverse set of compound libraries featuring unique central cores or chemotypes. The generative chemistry models embedded within Chemistry42 span over 40 distinct generative frameworks, integrating diverse AI architectures to propose molecular structures with tailored physicochemical and biological properties. This exhaustive exploration enabled scaffold hopping—a process of identifying and substituting core scaffolds of molecules—allowing the team to traverse chemical space beyond what traditional medicinal chemistry methods might achieve.

The initial phase of the project began with a precursor molecule exhibiting selectivity toward a specific KRAS mutant variant. From this starting point, the design process expanded swiftly, leveraging virtual screening modules of Chemistry42 that integrated rigorous structure-activity relationship (SAR) evaluations. In silico modeling refined potential candidates by simulating molecular interactions within the KRAS binding landscape, and iterative optimization was applied meticulously to the amino side chains to optimize binding affinity and selectivity profiles.

Following computational refinement, synthetic chemistry and biochemical assays validated the AI-generated candidates. The selected compounds demonstrated pan-KRAS inhibition with potencies measured in the upper nanomolar range, a noteworthy achievement given the high bar for KRAS-targeting agents. Importantly, these inhibitors exhibited mild selectivity favoring KRAS mutants over wild-type variants—up to a 4-fold difference in potency—signifying potential therapeutic indices that could mitigate off-target effects on normal cells. Furthermore, cell-based assays confirmed robust inhibitory activity in KRAS mutant tumor cell lines, emphasizing translational promise.

Metabolic profiling at this stage revealed the inhibitors possessed acceptable cytochrome P450 (CYP) inhibition profiles, thereby reducing concerns of adverse drug-drug interactions in vivo. This pharmacokinetic property is crucial for clinical development, where metabolic stability and interaction potential directly influence dosing, safety, and efficacy. The integration of AI-enabled predictive models in Chemistry42 likely expedited this aspect by foreseeing and flagging metabolic liabilities prior to synthesis.

Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, highlighted the transformative role of AI throughout this research. He emphasized how the convergence of generative chemistry and sophisticated molecular modeling has enabled the navigation of complex target landscapes, especially for proteins like KRAS that were once deemed refractory to drug discovery. This synergy underscores a paradigm shift where artificial intelligence is not merely a supplementary tool but a driving force accelerating the transition from computational concepts to tangible clinical candidates.

The research draws its lineage from Insilico’s foundational work dating back to 2016, when the company first articulated the concept of using generative AI to design novel therapeutic molecules in a peer-reviewed article. This pioneering vision laid the groundwork for the development of the Pharma.AI platform, which has since evolved into a comprehensive generative AI-powered ecosystem spanning biology, chemistry, medicine development, and research science. To date, Insilico Medicine has contributed over 200 scientific publications and holds more than 600 patents and patent applications, emphasizing its leadership at the intersection of AI and biotechnology.

By applying this sophisticated platform, Insilico Medicine is pushing the boundaries of what is achievable in medicinal chemistry, setting a new benchmark for computationally driven drug design. The successful development of pan-KRAS inhibitors of novel chemotypes signals a turning point in the fight against cancers driven by KRAS mutations. It also showcases the vital role AI can play in unlocking targets traditionally considered “undruggable,” potentially transforming treatment modalities across oncology and beyond.

As these novel inhibitors advance through preclinical validation, they represent promising candidates not only for therapeutic intervention but also as a testament to the growing impact of AI-driven approaches in modern drug discovery. The ability to integrate deep learning, molecular simulations, and automated synthesis in a tightly coupled pipeline may shorten drug development timelines, reduce costs, and increase the success rates of novel therapeutics.

Moreover, Insilico’s work hints at future applications where generative AI platforms might tackle an even wider array of targets with similar complexities and challenges. The collaboration between human expertise and AI augments medicinal chemistry with unparalleled speed and precision, potentially ushering in a new era of personalized and precision medicine.

For the broader scientific community, this success serves as a clarion call to embrace AI methodologies as not only complementary but essential in reimagining drug discovery workflows. Insilico Medicine’s Chemistry42 platform continues to evolve, integrating the latest technological innovations and expanding its reach across diverse therapeutic areas such as fibrosis, immunology, pain, obesity, metabolic disorders, and even novel fields like advanced materials and agriculture.

In essence, this breakthrough marks a remarkable convergence of computational chemistry, molecular biology, and artificial intelligence, delivering tangible progress against a historically elusive target and illuminating the pathway for future innovations in cancer therapeutics.

Subject of Research: Development of novel pan-KRAS inhibitors using generative AI-driven structure-based drug design and scaffold hopping.

Article Title: Identification of novel pan-KRAS inhibitors via Structure-Based drug design, scaffold hopping, and biological evaluation.

Web References:
https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00080
https://www.insilico.com

References:
Aladinskiy, V. et al. (2025) ‘Identification of novel pan-KRAS inhibitors via Structure-Based drug design, scaffold hopping, and biological evaluation,’ ACS Medicinal Chemistry Letters [Preprint].

Image Credits: Insilico Medicine

Keywords:
Generative AI, pan-KRAS inhibitors, medicinal chemistry, artificial intelligence, molecular modeling, scaffold hopping, drug discovery, oncology, druggable targets, structure-based design

KRAS mutations are notoriously implicated in multiple forms of aggressive cancers, including pancreatic, colorectal, and lung cancers. As a small GTPase, KRAS is pivotal in controlling cellular proliferation and survival pathways, and its hyperactivation due to mutation leads to uncontrolled tumor growth. Historically, KRAS has been deemed “undruggable” because of its extremely high affinity for GDP and GTP nucleotides and the absence of well-defined druggable pockets, hampering the development of effective inhibitors. Insilico Medicine’s breakthrough presents a compelling solution to this long-standing challenge by employing innovative AI-driven drug design methodologies that transcend traditional trial-and-error approaches.

The research commenced by evaluating an existing molecule known for selective inhibition against a particular KRAS variant. Leveraging this molecular baseline, the team sought to identify structurally novel compounds capable of inhibiting all prevalent KRAS mutants—hence the term pan-KRAS inhibitors. Utilizing the generative modules integrated into Chemistry42, researchers synthesized a diverse virtual compound library characterized by various central chemical cores. This diversity was critical for sculpting a new chemical space capable of binding to KRAS in unique and efficacious ways, transcending the limitations of previously known inhibitors.

Scaffold hopping, a strategy to exchange the central core structure of a molecule while retaining or enhancing activity, was rigorously employed through Chemistry42’s virtual screening capabilities. This AI-powered process allowed the team to efficiently explore a vast chemical space, identifying novel core structures that maintain favorable interactions with KRAS binding sites. Concurrently, a suite of molecular modeling and structure-activity relationship (SAR) analyses refined candidate molecules, iteratively optimizing their affinity, selectivity, and pharmacokinetic parameters. Such detailed computational analysis formed the backbone of candidate selection before advancing to physical synthesis.

Once promising molecules were identified, synthesis protocols were established, followed by meticulous biological evaluations. The candidates were tested for their inhibitory potency against multiple KRAS mutants and compared against wild-type KRAS to ascertain selectivity profiles. Encouragingly, the hit series demonstrated a mild selectivity skew towards mutant KRAS variants, exhibiting up to a 4-fold difference in potency, which is a meaningful threshold to minimize off-target effects on normal cellular function. Additionally, the compounds showcased robust inhibition in KRAS mutant cell lines, a crucial preclinical indicator of therapeutic potential.

An often-overlooked hurdle in early drug discovery is the metabolic profile of candidate molecules. Insilico’s research addressed this by assessing cytochrome P450 (CYP) inhibition, a critical determinant of drug-drug interactions and overall drug safety. The pan-KRAS inhibitors displayed acceptable CYP inhibition profiles at this investigative stage, underlining their potential for favorable pharmacodynamics and reduced toxicity risks, which are essential for progressing towards clinical development. This balanced optimization of efficacy and druggability parameters epitomizes the power of AI-enabled drug discovery pipelines.

The fusion of artificial intelligence and human expertise remains at the heart of this scientific triumph. Alex Zhavoronkov, PhD, Founder, and CEO of Insilico Medicine, expressed enthusiasm regarding the transformative potential of the Chemistry42 platform. He emphasized how the integration of advanced molecular modeling and scaffold hopping techniques has facilitated the tackling of KRAS, a target previously considered refractory to drug intervention. This achievement not only validates AI’s role in drug discovery acceleration but also highlights the synergy between computational models and empirical validation.

Insilico Medicine’s journey into AI-driven molecular design dates back to 2016 when the company first introduced the concept of generative AI for novel molecule creation in peer-reviewed literature. This foundational work paved the way for Pharma.AI, a commercial generative AI platform that now spans biology, chemistry, medicinal development, and scientific research. Over the years, Insilico has continuously integrated technological innovations into Pharma.AI, enhancing its capability to innovate rapidly across various fields, including oncology, fibrosis, immunology, pain management, and metabolic disorders.

Beyond oncology, Insilico Medicine applies their AI-driven discovery processes to a broad spectrum of diseases and sectors. Their cutting-edge automated laboratories and in-house drug discovery capabilities enable effective translation of AI-generated candidates into tangible preclinical and clinical assets. Furthermore, the company extends the utility of Pharma.AI beyond healthcare, venturing into advanced materials science, agriculture, nutrition, and veterinary medicine, demonstrating the versatility and scalability of AI in scientific innovation.

The published results of this research, appearing in ACS Medicinal Chemistry Letters, delineate a promising roadmap for future pan-KRAS therapeutics. By embracing a novel chemotype paradigm and coupling it with robust generative and structure-based design methods, Insilico has set the stage for accelerated clinical candidate development against KRAS-driven malignancies. The comprehensive strategy amalgamates AI’s capability to interpret and generate chemical structures with human insight into biological systems and medicinal chemistry, heralding a new era in targeted cancer drug discovery.

In summary, Insilico Medicine’s innovative use of Chemistry42 and generative AI technologies has culminated in the discovery of potent pan-KRAS inhibitors characterized by unique chemical scaffolds, promising selectivity, and favorable drug metabolism profiles. This milestone redefines the potential of tackling “undruggable” targets through AI-enhanced drug design, providing hope for new therapeutic options against cancers with unmet medical needs. As AI continues to evolve and integrate deeper into the drug discovery pipeline, breakthroughs like this exemplify its capacity to transcend traditional pharmaceutical challenges and accelerate the fight against complex diseases.

Subject of Research: Development of novel pan-KRAS inhibitors using AI-driven generative chemistry.

Article Title: Identification of novel pan-KRAS inhibitors via Structure-Based drug design, scaffold hopping, and biological evaluation.

Web References:

• https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00080
• http://dx.doi.org/10.1021/acsmedchemlett.5c00080

References:
[1] Aladinskiy, V. et al. (2025) "Identification of novel pan-KRAS inhibitors via Structure-Based drug design, scaffold hopping, and biological evaluation," ACS Medicinal Chemistry Letters [Preprint].

Image Credits: Insilico Medicine

Keywords

Generative AI, Oncogenes, Molecular Targets, Medicinal Chemistry